Reactivity of human placental chorionic plate vessels from pregnancies complicated by intrauterine growth restriction (IUGR).
A successful pregnancy is dependent on liberal placental perfusion via the maternal and fetal circulations. Doppler waveform analyses of umbilical arteries suggest increased resistance to flow in the fetoplacental circulation of pregnancies complicated by intrauterine growth restriction (IUGR). Neither the site nor the mediators responsible for this altered vascular reactivity are known, to date. In placentas in normal pregnancy, reduced oxygenation promotes contraction of the in vitro-perfused placental cotyledon and modulates agonist-induced contraction of chorionic plate arteries and veins. Placental oxygenation has also been suggested to be reduced in IUGR. We tested the hypothesis that oxygen tension could directly modify placental chorionic plate vessel vasoreactivity in IUGR. Small arteries and veins from the chorionic plate were dissected from biopsies from placentas of pregnancies complicated by IUGR and were studied using parallel wire myography. Vasoconstriction at 20%, 7%, and 2% oxygen was assessed utilizing the thromboxane mimetic U46619. Experiments were also performed in the presence of 4-aminopyridine (4AP), a blocker of voltage-gated potassium channels. Increased oxygenation reduced venous vasoconstriction but did not modify arterial vasoconstriction. 4AP increased basal tone in arteries and veins. We suggest that venoconstriction in response to hypoxia may provide a mechanism for increased fetoplacental vascular resistance associated with IUGR.
Wareing
Mark
M
Division of Human Development, Maternal and Fetal Health Research Center, The University of Manchester, St. Mary's Hospital, Manchester M13 0JH, United Kingdom. Mark.Wareing@manchester.ac.uk
Greenwood
Susan L
SL
Fyfe
Gregor K
GK
Baker
Philip N
PN
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D015761:4-Aminopyridine / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D001158:Arteries / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005317:Fetal Growth Retardation / Q000503:physiopathology*; D006801:Humans; D066298:In Vitro Techniques; D007231:Infant, Newborn; D009213:Myography / Q000379:methods; D010100:Oxygen / Q000378:metabolism / Q000494:pharmacology; D010920:Placenta / Q000098:blood supply* / Q000187:drug effects / Q000502:physiology; D021041:Placental Circulation; D026902:Potassium Channel Blockers / Q000494:pharmacology; D011247:Pregnancy; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014680:Veins / Q000187:drug effects
D026902:Potassium Channel Blockers; D014662:Vasoconstrictor Agents; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D015761:4-Aminopyridine; D010100:Oxygen